Exosome Therapy Exposed: 9 Questions Providers Need Answered
17 days ago
- Exosomes work by reprogramming the immune system, not by “adding” cells. Dr. Park explains that the core mechanism appears to be a shift from a TH1/M1 inflammatory immune profile to a TH2/M2 regenerative one — effectively coaxing local stem cells into a more primitive, healing-oriented state, rather than simply delivering new cellular material.
- Sourcing and manufacturing quality are the single biggest risk factor for providers. Because exosome potency can’t be reliably measured (particle-count testing is easily manipulated), Dr. Park stresses that provider trust in a manufacturer’s rigor, sterility practices, and lot-tracking matters more than marketed particle counts — and that this is where most of the real risk lives.
- Legal and malpractice exposure hinges on consent, intent, and deviation from standard of care. Since exosome therapy isn’t FDA-approved, Dr. Park frames malpractice risk around three pillars — informed consent, absence of malice, and deviation from standard of care — and encourages providers to document thoroughly and price and practice in a way they’re personally comfortable defending.
Comments